Matador Resources Company Cuts Target Price to $60 From $68
MTDR•Related News
Phio Pharma wins U.S. patent allowance for BRD4-targeting INTASYL compound PH-894
PHIO•
Chicago Atlantic Real Estate Finance Q2 FY26 net income falls 16% to $7.47 million; revenue dips 8% to $15.22 million
REFI•
Gain Therapeutics Q2 FY26 net loss narrows to $0.11 a share; R&D expenses fall 24.64% to $2.1 million
GANX•
CETIN Networks Slovakia selects Radcom under multi-year mobile network assurance contract
RDCM•
Prelude Therapeutics Q2 EPS USD -0.14
PRLD•